D Molecular Therapeutics, Inc. ( (FDMT) ) has released its Q3 earnings. Here is a breakdown of the information 4D Molecular Therapeutics, Inc.

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

Sponsored content Eye health is something many of us take for granted. But looking after our eyes is important for ...

Take-Two Interactive CEO Strauss Zelnick has illuminated the company's position on AI tools and how they will be adopted for ...

To protect your eye health and support your vision, these are 10 simple things you can do every day for your eyes.

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

Meta's AI capabilities may soon expand Instagram's feature set, allowing users to personalize their profiles with ...

Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsEdward Berg - Senior Vice President and ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...